Geda Chance to Buy the Post-ASCO Pullback

Research evidence excerpt

Geda Chance to Buy the Post-ASCO Pullback

Biotechnology - Oncology & Rare Diseases

Oncology - Market Overweight

CELCUITY, INC. (CELC) June 28, 2026

Geda Chance to Buy the Post-ASCO Pullback Rating:

Outperform

The Wolfe Byte Price: $99.95

Shares are down ~25% post-ASCO, below pre-catalyst. The 13+ mo mPFS didn't Price Target:

print but the control arm also underperformed. Geda triplet's impressive HR $160

of 0.50 beat the implied bridge (~0.55-0.60) and is what we think will drive % Upside:

60.1%prescribing. Fundamentals intact, maintain OP.

View CELC Model

View Comp Table

We touched base with mgmt, and the team appears ready to execute on Company Information

commercialization (PDUFA date in July). CELC has hired 90 reps, 10 managers, plus 52-Week Range $12 - $145

MSLs, marketing/commercial teams (e.g., full 150-person org kicked off in Chicago Market Cap. (MM) $4,874

early May, reps now field-profiling accounts). Mgmt noted strategic prep and payer Enterprise Value (MM) $5,380

Shares Out. (MM) 48.8

teams are in place. Mgmt has commented that hiring quality is strong; no recruiters Avg. Value Traded (MM) $141.00

utilized and reps include predominantly veterans from prior breast cancer launches SI% of Float 28.9%

(~17 years average oncology experience).

Modeling a realistic launch trajectory. We discussed with mgmt the projected launch 140

ramp and time to peak sales based on historical precedents. A market penetration 120

rate of ~1% per month, reaching peak penetration over ~36–42 months, appears to 80

be a reasonable assumption. A temporary miscellaneous J-code with 6-month review 60

cycles represents standard reimbursement friction for any buy-and-bill drug, and 20

mgmt has expressed confidence in the IV launch within the community setting. For 0